Schorno Dean L 4

4 · RIGEL PHARMACEUTICALS INC · Filed Jun 3, 2026

AI-generated summary of this filing

Updated Jun 3, 2026

Rigel Pharmaceuticals CFO Dean Schorno Exercises Stock Options

What Happened

Dean L. Schorno, Chief Financial Officer of Rigel Pharmaceuticals (RIGL), exercised stock options on June 1, 2026, resulting in the acquisition of 3,381 common shares. He paid $50,139 in aggregate exercise price ($22,440 for 1,200 shares at $18.70 and $27,699 for 2,181 shares at $12.70).
As part of the exercise, 928 shares were withheld to satisfy tax withholding obligations (reported as a disposition under code F) and valued at $27,710 (price $29.86). The filing also shows the option/derivative interests for 1,200 and 2,181 shares were converted (reported as derivative dispositions at $0.00).

Key Details

Transaction date: June 1, 2026; Form 4 filed June 3, 2026 (timely filing).
Exercise details: 1,200 shares @ $18.70 = $22,440; 2,181 shares @ $12.70 = $27,699; total cash paid $50,139.
Tax withholding: 928 shares withheld @ $29.86 = $27,710 (code F).
Derivative conversion: 1,200 and 2,181-option units converted to common stock (reported as M and derivative dispositions at $0.00).
Shares owned after transaction: not specified in the provided filing excerpt.
Footnotes: adjustments reflect a 1-for-10 reverse split effective June 27, 2024 (F1). Vesting schedules noted for the option grants (monthly vesting over 3–4 years; F2, F3).

Context

This was an option exercise (code M) with withholding to cover taxes (code F), not an open-market sale. That is a routine administrative transaction converting vested options into shares and meeting tax obligations, not a straightforward buy/sell signal.
The filing indicates vesting schedules and a prior reverse split; no late filing was indicated.

Form 4

Period: 2026-06-01

EVP & Chief Financial Officer

Transactions

Exercise/Conversion
Common Stock
2026-06-01$18.70/sh+1,200$22,440→ 77,537 total
Exercise/Conversion
Common Stock
[F1]
2026-06-01$12.70/sh+2,181$27,699→ 79,718 total
Tax Payment
Common Stock
2026-06-01$29.86/sh−928$27,710→ 78,790 total
Exercise/Conversion
Employee Stock Option (right to buy)
[F2]
2026-06-01−1,200→ 9,632 total
Exercise: $18.70Exp: 2033-01-26→ Common Stock (1,200 underlying)
Exercise/Conversion
Employee Stock Option (right to buy)
[F1][F3]
2026-06-01−2,181→ 13,518 total
Exercise: $12.70Exp: 2034-01-23→ Common Stock (2,181 underlying)

Footnotes (3)

[F1]These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.
[F2]The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period.
[F3]The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the issuer through each such period.

Signature

/s/ Raymond Furey (Attorney-in-Fact)|2026-06-03

1 file